
nature

PARKINSON'S DISEASE



COVER ART: NIK SPENCER

Supplement EditorMichelle Grayson

Production EditorDonald McDonald

Picture Research

Madeline Hutchinson

Nature Art Editor Martin Harrison

Production Controller Emilia Orviss

Web Production Editor Dan Foley

Sub Editors

Victoria Kitchener, Tony Scully

Elena Woodstock, Hannah Phipps

Managing Editor Nick Campbell

Magazine Editor

Tim Appenzeller

Project Manager Helen Anthony

Editor in Chief, Nature Publications

Philip Campbell

Sponsorship

Reya Silao, Stephen Russell

Editorial Advice

Marie-Thèrése Heemels, Claudia Wiedemann, Heather Wood, Peter Kirkpatrick, Bethan Hughes



nature publishing group

CITING THE OUTLOOK

XXX, No. XXXX suppl., Sxx-Sxx (2010).

Nature Outlooks are sponsored supplements that aim to

to the sponsor, while satisfying the editorial values of

advertising/resources/pdf/outlook_guidelines.pdf.

stimulate interest and debate around a subject of interest

Nature and our readers' expectations. The boundaries of

sponsor involvement are clearly delineated in the Nature

Cite as a supplement to Nature, for example, Nature Vol

Outlook editorial guidelines available at www.nature.com/

here are many success stories in the history of Parkinson's disease. Our understanding of the condition has greatly evolved since it was first identified as the shaking palsy 193 years ago. We have made progress in defining the underlying pathology and tracking disease progression, and better treatments improve patient quality of life. Yet, a cure remains elusive.

Unlike other neurodegenerative conditions, Parkinson's disease has had a successful symptomatic drug available for more than 40 years. Levodopa is the mainstay of Parkinson's disease treatment, but although its pharmacology and delivery have been altered and improved over the years, it is still far from ideal. And herein lies perhaps the ultimate frustration: despite several decades of searching, levodopa is still the best there is.

That is not the only challenge. Can we detect the disease before major, perhaps irreversible degeneration has occurred? What will it take to replicate this disease in animal models to enhance our understanding of it and aid development of novel treatments? And how can new, potentially disease-modifying therapies be appropriately tested in patients?

As this *Nature Outlook* reveals, we might be on the brink of a revolution in the diagnosis and treatment of Parkinson's disease. The frustration of failing to find a simple or single cause is giving way to the hope that the complex web of gene and protein interactions might be starting to untangle. Candidate biomarkers for earlier diagnosis are emerging, and many new and exciting treatments are working their way into the clinic.

We are pleased to acknowledge financial support from Abbott in producing this Outlook. As always, *Nature* carries sole responsibility for all editorial content.

Michelle Grayson,
Associate Editor, Nature Outlooks

VISIT THE OUTLOOK ONLINE

The Nature Outlook Parkinson's Disease supplement can be found at www.nature.com/nature/outlook/parkinsons/. It features all newly commissioned content as well as a selection of relevant previously published material. All featured articles will be freely available for 3 months.

SUBSCRIPTIONS AND CUSTOMER SERVICES

For UK/Europe (excluding Japan): Nature Publishing Group, Subscriptions, Brunel Road, Basingstoke, Hants, RG21 6XS, UK. Tel: +44 (0) 1256 329242.



contents

- Secrets of the shaking palsy Jim Schnabel
- S6 Levodopa: the story so far Alison Abbott
- Parkinson's disease: a model dilemma M. Flint Beal
- S11 Biomarkers: casting the net wide
- Slowing the decline Ruth Williams
- S15 Treatment frontiers
 Kerri Smith

collection

S19 Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry

Alexxai V. Kravitz et al.

- S24 Genome-wide association study reveals genetic risk underlying Parkinson's disease
- S29 Parkinson disease: Depression and anxiety in Parkinson disease

Pablo Martínez-Martín & Javier Damián

S31 Missing pieces in the Parkinson's disease puzzle

Jose A. Obeso et al.

S40 Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease

Wataru Satake et al.

Subscriptions and customer services for Americas – including Canada, Latin America and the Caribbean: Nature Publishing Group, 75 Varick St, 9th floor, New York, NY 10013-1917, USA. Tel: +1866 363 7860 (US/Canada) or +1 212 726 9223 (outside US/Canada).

CUSTOMER SERVICES

Feedback@nature.com

Copyright © 2010 Nature Publishing Group

www.nature.com/outlooks